Orphan drugs and the NHS: consider whom drug regulation is designed to protect.
作者信息
Marshall Tom
出版信息
BMJ. 2005 Nov 12;331(7525):1144. doi: 10.1136/bmj.331.7525.1144-b.
Abstract
摘要
相似文献
1
Orphan drugs and the NHS: consider whom drug regulation is designed to protect.
BMJ. 2005 Nov 12;331(7525):1144. doi: 10.1136/bmj.331.7525.1144-b.
2
Orphan drugs and the NHS: should we value rarity?
BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016.
3
Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.
BMJ. 2005 Nov 12;331(7525):1144-5. doi: 10.1136/bmj.331.7525.1144-c.
4
[Orphan drugs: drugs for rare diseases].
Dtsch Med Wochenschr. 2010 May;135(18):p17.
5
Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.
Appl Health Econ Health Policy. 2013 Feb;11(1):1-3. doi: 10.1007/s40258-012-0004-y.
6
[Orphan drugs: towards an economic evaluation].
Rev Prat. 2012 Jan;62(1):91-4.
7
The challenges of orphan drugs and orphan diseases: real and imagined.
Clin Pharmacol Ther. 2012 Aug;92(2):151-3. doi: 10.1038/clpt.2012.72.
8
[Orphan drugs: availability, reliability and reimbursement].
Ned Tijdschr Geneeskd. 2012;156(17):A4252.
9
Orphan drugs revisited.
QJM. 2006 May;99(5):341-5; discussion 350-1. doi: 10.1093/qjmed/hcl033. Epub 2006 Feb 27.
10
[Drugs for rare diseases].
Lakartidningen. 2010;107(16):1043.
本文引用的文献
1
Orphan drugs and the NHS: should we value rarity?
BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016.
Zotero 插件